An eye-opening solution for tissue samples – launch of NaveniFlex™ Tissue Looking for protein-protein interactions or post-translational modifications in tissues? We’ve got you covered. The advanced Naveni™ proximity ligation technology we developed for NaveniFlex™ Tissue kits are tailor-made to overcome common background challenges in tissue samples. The kits are optimized for tissue samples to deliver…
Discover the secret life of proteins – simultaneously visualize two proteins in a free and complex state Ever wish there were a way to take a snapshot of two proteins as they interact or remain unbound? Now, the door is open to study protein interplay and functional states while keeping the structural integrity of cells.…
Here to make a difference – the first PD1/PD-L1 interaction assay Immune checkpoint inhibitors have revolutionized cancer immunotherapy, and more than 3000 anti-PD1/PD-L1 therapies are currently in clinical trials. The leading technology used to determine whether a patient is likely to benefit from PD1/PD-L1 immunotherapy is PD-L1 immunohistochemistry. However, this test doesn’t reveal whether the…
Low signal and multiple non-specific bands in your Western Blot? Learn how the authors of a recently published paper surpassed the problems and created a sensitive and specific Western Blot with Naveni™ Proximity Ligation Technology. Dr. Athanasios Alexandris is a postdoc at the department of Pathology at Johns Hopkins in the lab of Professor Vassilis…
Navinci Diagnostics AB, a Swedish life science company developing innovative tools for spatial proteomics research, announces the closing of a SEK 90 million financing round. The round was led by Segulah Medical Acceleration (”SMA”), a Scandinavia-based life science-focused investment company, together with existing shareholders, including Landegren Gene Technology AB, Nexttobe AB, and Beijer Ventures AB.…
Navinci has developed several in situ Proximity Ligation Assays, providing deep biological knowledge about the signaling pathways of PD1 and PD-L1. The first assay available to order is: Naveni pY PD1 (phosphorylated PD1) PD1 PD-L1 signaling has proven significant in cancer progression, and therapies with immune checkpoint inhibitors have revolutionized cancer treatment efficacy. Despite the…
COMING SOON Naveni PD1/PD-L1 Protein-protein interaction (PPI): Proximity Ligation assay for detection of PD1/PD-L1 interaction Naveni pY PD1 Protein post-translational modifications (PTM): Proximity Ligation assay for detection of phosphorylated PD1 Contact us
New publication out! Wåhlén et al. have just published the article: Differential impact of lipid raft depletion on platelet-derived growth factor (PDGF)-induced ERK1/2 MAP-kinase, SRC and AKT signaling – ScienceDirect In the study, they analyzed the co-localization of PDGFR-β and GRB2, PI3K or clathrin, using our Naveni Proximity Ligation Technology. Citation: “For this purpose, NaveniFlex…
Quantify phospho-VEGFR2 in situ Navinci is expanding the Naveni PTM product line! Quantify phosphorylated VEGFR2 with outstanding signal-to-noise ratio. Receptor tyrosine kinases (RTKs) are involved in cellular processes and altered phosphorylation states may lead to disturbed signaling pathways, tumor progression, and cancer. Specific tools for quantifying phosphorylation of RTKs in situ have been requested for…
LAUNCH NEWS Navinci is taking the next step to meet the needs of the pathology field. NaveniBright is a new product line with chromogenic readout. The in situ kits are based on our Naveni Proximity Ligation Technology and significantly enhance the chromogenic signal, providing you with stronger and more accurate staining. The assay gives you detailed…
Navinci Diagnostics partners with Ozyme for the distribution of Naveni products in France. Ozyme is a highly skilled partner with deep insight into immunoassays and antibody-related research. Ozyme will make it possible for our French customers to interact with a local distributor with great knowledge within the biotech field. We look forward to working closely with Ozyme;…
Introducing Naveni target-specific assays for phosphorylated RTK’s: EGFR, HER2, PDGFR-beta, MET We are now launching target-specific Naveni in situ proximity ligation assays for phosphorylated receptor tyrosine kinases EGFR, HER2, PDGFR-beta and MET. The assays are based on dual epitope recognition by two primary Navenibodies, that generate an amplified signal when bound in close proximity. This…
